Clinical trials: completed, sponsored by Dana-Farber Cancer Institute
Cancer, Quality of Life
The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
- Conditions
- Cancer, Quality of Life, Anxiety, Depression
- Trial name
- PRISM-AC (NCT03668223)
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- 5 sites in United States
- Volunteers
- 269 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer Prevention, Weight Loss
PROFAST Intervention in Precursor Multiple Myeloma
This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM)…
- Conditions
- Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS
- Trial name
- PROFAST (NCT05565638)
- Testing
- Prolonged Fasting Intervention, EDUCATION CONTROL
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.
- Trial name
- NCT03414684
- Testing
- Carboplatin, Nivolumab
- Where
- 10 sites in United States
- Volunteers
- 78 people
- Sponsor
- Dana-Farber Cancer Institute
Thyroid Cancer
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise.
- Trial name
- NCT00936858
- Testing
- RAD001
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Thyroid Cancer
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
This research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells…
- Trial name
- NCT02657551
- Testing
- Regorafenib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
Drug/Agent Toxicity by Tissue/Organ, Leukemia
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
RATIONALE: L-asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia, but is also associated with notable side-effects, including hypersensitivity, pancreatitis, and thrombosis.
- Trial name
- NCT00400946
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 8 sites in United States, Canada
- Volunteers
- 800 people
- Sponsor
- Dana-Farber Cancer Institute
Inflammatory Breast Cancer (IBC)
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib.
- Trial name
- NCT02876302
- Testing
- Ruxolitinib, Paclitaxel, Doxorubicin
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer…
- Trial name
- NCT03716739
- Testing
- Testosterone Cypionate 100 MG/ML
- Where
- 3 sites in United States
- Volunteers
- 136 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Coronary Artery Disease
Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
This study is about testing whether exercise will improve fitness and lessen risk factors related to heart disease, diabetes, and obesity in Latina breast cancer survivors.
- Conditions
- Breast Cancer, Coronary Artery Disease, Stroke, Type2 Diabetes
- Trial name
- NCT04717050
- Testing
- Progressive combine training (PCT), Attention Control (AC)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Solid Tumor
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: Pembrolizumab AMG386
- Trial name
- NCT03239145
- Testing
- Pembrolizumab, Trebananib
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Abemaciclib With or Without Atezolizumab for mCRPC
This trial is testing whether a molecularly targeted chemotherapy drug called abemaciclib and an immunotherapy drug called atezolizumab, alone or in combination, are effective in shrinking or preventing the growth of metastatic…
- Trial name
- NCT04751929
- Testing
- Abemaciclib, Atezolizumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Pediatric Cancer, CNS Tumor, Childhood
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
This research study is examining a preventive skin care regimen for children diagnosed with a brain tumor and receiving anti-cancer therapy with a MEK, Pan-RAF, or BRAF inhibitor.
- Conditions
- Pediatric Cancer, CNS Tumor, Childhood, Skin Inflammation
- Trial name
- NCT04479514
- Testing
- Warm Baths or Showers, Moisturizer, SPF 30 or Higher Suncreen
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant…
- Conditions
- Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
- Trial name
- NCT02362997
- Testing
- Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 82 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
This research study is studying the combination of a drug called atezolizumab and a radiation procedure called stereotactic radiosurgery (SRS) as a possible treatment for triple-negative breast cancer that has spread to the…
- Trial name
- NCT03483012
- Testing
- Atezolizumab, Stereotactic radiosurgery (SRS)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
This research study is evaluating a drug combination called Imprime PGG and Rituximab as a possible treatment for relapsed/refractory indolent B cell non-Hodgkin lymphomas (NHL).
- Trial name
- NCT02086175
- Testing
- Imprime PGG, Rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
This research study is evaluating a combination of drugs called Ofatumumab and Idelalisib as a possible treatment for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL).
- Trial name
- NCT02135133
- Testing
- Idelalisib, Ofatumumab
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Dana-Farber Cancer Institute
Gynecologic Cancer, Gastrointestinal Cancer
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
This research study is evaluating a new intervention, BOLSTER, which was designed to provide more support for patients with gynecologic and gastrointestinal cancers and their caregivers after a hospitalization.
- Trial name
- NCT03367247
- Testing
- BOLSTER, Enhanced Discharge Planning (EDP)
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial
This research study is evaluating acupuncture, a medical therapy in which hair-thin, stainless steel needles are shallowly inserted into specific points to help the body's natural healing process, as a possible treatment to…
- Trial name
- NCT03783546
- Testing
- Acupuncture, Usual Care
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Ganetespib is a drug that may stop cancer cells from growing. This drug has been used in other research studies and laboratory experiments.
- Trial name
- NCT01560416
- Testing
- Fulvestrant, Ganetespib
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Insomnia, Insomnia Due to Medical Condition
Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)
The purpose of the study is to learn if a single online education session, with or without individualized coaching sessions, can help improve young adult cancer survivors' (YACS) sleep.
- Conditions
- Insomnia, Insomnia Due to Medical Condition, Cancer
- Trial name
- NCT05358951
- Testing
- STEP-YA with Coaching, STEP-YA without Coaching
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Dana-Farber Cancer Institute